No significant differences emerged, with respect to the combined endpoint of mortality and signs/symptoms of ventricular failure, between the two thrombolytic drugs (tPA 23.1%, SK 22.5%, RR 1.04, 95%CI .95-1.13) or between heparin and no heparin (heparin 22.7%, no heparin 22.9%, RR 0.99, 95%CI 0.91-1.08);

As for mortality alone, on the population of 20.891 patients including the international extension, no significant differences emerged between the two thrombolytic treatments (tPA 8.9%, SK 8.5%, RR 1.05, 95%CI 0.95-1.16) or between heparin and no heparin (heparin 8.5%, no heparin 8.9%, RR 0.95, 95%CI 0.86-1.04);

In this population, a small - albeit significant - excess of stroke was found among patients treated with alteplase with respect to those treated with streptokinase: tPA 1.3%, SK 0.9% (RR 1.41, 95%CI 1.09-1.83).